Heidi Reiter, NP
Nurse Practitioner · Bismarck, NDNPI 1659635738
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,252 of the $2,023 with a category attached, or 61.9%. 8 manufacturers reported payments, led by Pulmonx Corporation at 59.3% of the total. 2025 is the largest year on record at $1,391, more than ten times the $74 reported in 2021. Among nurse practitioner clinicians in ND with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 19 payments — averaging $106.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pulmonx Corporation$1K
- AstraZeneca$241
- Boehringer Ingelheim$142
- United Therapeutics Corporation$138
- Actelion Pharmaceuticals US, Inc.$110
- Regeneron Healthcare Solutions, Inc.$99
- plus $92 from 2 others
What the payments were for
- Travel & lodging$77038%
- Food & beverage$1,25262%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pulmonx Corporation | 4 | $1,199 |
| AstraZeneca | 3 | $241 |
| Boehringer Ingelheim | 3 | $142 |
| United Therapeutics Corporation | 3 | $138 |
| Actelion Pharmaceuticals US, Inc. | 1 | $110 |
| Regeneron Healthcare Solutions, Inc. | 3 | $99 |
| GSK | 1 | $74 |
| Verona Pharma, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPHYR ENDOBRONCHIAL VALVE$1,140
- PULMONX CHARTIS TABLET CONSOLE$1,140
- CHARTIS CATHETER$1,140
- ZEPHYR DELIVERY CATHETER$1,140
- AIRSUPRA$113
- UPTRAVI$110
- OPSUMIT$110
How this compares
$2,023 in reported general payments places this provider in the 90th percentile of 455 nurse practitioner providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 17 | $225,868 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 184 | $143,311 |
| XolairOmalizumab | 30 | $101,351 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 84 | $55,988 |
| Spiriva RespimatTiotropium Bromide | 66 | $50,440 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 53 | $39,549 |
| Breo ElliptaFluticasone/Vilanterol | 75 | $36,174 |
| Spiriva HandihalerTiotropium Bromide | 42 | $33,474 |
| Incruse ElliptaUmeclidinium Bromide | 58 | $33,274 |
| Pirfenidone | 22 | $30,901 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 54 | $29,390 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 107 | $20,064 |
| DuleraMometasone/Formoterol | 48 | $16,101 |
| Advair HfaFluticasone Propion/Salmeterol | 35 | $14,041 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $14,004 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $142 | $340,098183 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $74 | $242,150371 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $241 | $53,55486 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 455 nurse practitioner providers in North Dakota.
Other nurse practitioner in Bismarck
- Lisa ClairmontBismarck$15K
- McKinzie NussBismarck$7K
- Paula MochBismarck$5K
- Trina KaiserBismarck$5K
- Cassie HoltBismarck$5K
- Katherine CarvellBismarck$5K
- Shih Ru MartinBismarck$5K
- Janel OlsonBismarck$4K
- Mallorie EmoryBismarck$3K
- Kayla CoferBismarck$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.